CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis
CDKN2A was first identified as melanoma predisposition tumour suppressor gene and has been successively studied. The previous researches have not established any noteworthy association with breast cancer. Therefore, through extensive literature search and in-silico analysis, we have tried to focus on the role of CDKN2A in breast cancer. CDKN2A variants in breast cancer were collected from different databases. The overall percentage of variants (approximately 5.8%) and their incidence frequency in breast cancer cases were found to be very low as compared to the number of samples screened in different studies. Exon 2 was identified as the major region of alternations. Approximately 42.8% were entire gene deletions, while 24.2% were missense mutations. These variants cannot be ignored because of their pathogenic effects as interpreted by the bioinformatics tools used in the present study. Earlier studies have shown that CDKN2A excludes the predisposition of germline variants, but interestingly shares common breast cancer germline variants with other carcinomas. Most of the data have revealed this gene as rarely mutated or deleted in breast cancer. However, few association studies have shown that in addition to being a ‘multiple’ tumour suppressor gene, it is mutated/deleted more in breast cancer cell lines as compared to breast cancer tissues or blood samples; thus, this gene cannot be neglected as a breast cancer candidate gene. The deletion/malfunctioning of CDKN2A in different tumours including breast cancer has recently led to the discovery of many clinical CDK inhibitors. Furthermore, these collected genetic variants will also be helpful in developing diagnostic, preventive, and treatment approaches for patients.
KeywordsBreast cancer Variant analysis CDKN2A P16
Compliance with ethical standards
Conflict of interest
Authors have no conflict of interest.
- 6.Agarwal P, Mohammad F, Kabir L, Deinnocentes P, Bird RC. Tumour suppressor gene p16/INK4A/CDKN2A and its role in cell cycle exit, differentiation, and determination of cell fate. In: Cheng Y (ed). Tumor Suppressor Genes. InTech. 2012;1–35.Google Scholar
- 8.Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res. 1996;2:1993–8.Google Scholar
- 30.Peng D, Zhang H, Sun G. The relationship between P16 gene promoter methylation and gastric cancer: a meta-analysis based on Chinese patients. J Cancer Res Ther. 2014;10 Suppl:292–5.Google Scholar
- 31.Berggren P, Kumar R, Sakano S, et al. Detecting homozygous deletions in the CDKN2A(p16INK4a)/ARF(p14ARF) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res. 2003;9:235–42.Google Scholar
- 38.Jones A, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby A, Tomlinson I, Sawyer E, Phyllodes Tumour Consortium. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoural genetic heterogeneity and new genetic changes on recurrence. J Pathol. 2008;214:533–44.CrossRefGoogle Scholar
- 39.Herman JG, Merlo A, Mao L, Herman G, Lapidus G, Issa J, Davidson E. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers DNA methylation in all common human cancers. Cancer. 1995;55:4525–30.Google Scholar
- 40.Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5′ CpG island of the p16/CDKN2 tumour suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995;55:4531–5.Google Scholar
- 44.Betts MJ, Russell RB. Amino acid properties and consequences of substitutions. In: Bioinformatics for geneticists. Chichester: Wiley, p. 289–316. https://onlinelibrary.wiley.com/doi/pdf/10.1002/0470867302.ch14.
- 51.Ramos-Esquivel A, Hernandez-Steller H, Savard M-F, Landaverde DU. (2018) Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. Breast Cancer. https://doi.org/10.1007/s12282-018-0848-6.Google Scholar
- 55.Ilorasertib in treating patients with CDKN2A-deficient advanced or metastatic solid cancers that cannot be removed by surgery. 2015–2017. clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT02540876 (Identifier: NCT02540876).
- 66.Jones A, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby A, Tomlinson I, Sawyer E, Phyllodes Tumour Consortium. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol. 2008;214:533–44.CrossRefGoogle Scholar
- 67.Brenner AJ, Aldaz CM. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res. 1995;55:2892–5.Google Scholar
- 74.Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. 1994;54:5262–4.Google Scholar
- 75.Spirin K, Simpson JF, Miller CW, Koeffler HP. Molecular analysis of INK4 genes in breast carcinomas. Int J Oncol. 1997;11:737–44.Google Scholar